Innoviva (INVA) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.31B, a trailing price-to-earnings ratio of 39.2 and a free-cash-flow yield of 11.9%. Over the most recent reported fiscal year, revenue grew 14.7% and free cash flow per share fell 11.5%. Nama's AI scorecard rates it Buy, 8.2 out of 10. On 12-month momentum it ranks in the lagging band of its market.
AI scorecard
Buy · 8.2/10
Clearly positive, short of the top band. As of Nov 20, 2026.
Momentum
Lagging · -1.2% over 12 months ex. last
Second-worst fifth of its market on the past year's move.
Shariah screen
Not Shariah Compliant
At least one of the three ratios or the industry test failed.
Off its high
-26.8%
How far the last close sits under the highest price of the past five years.
Market cap
$1.31B
Trailing P/E
39.2
Price / book
1.2
Price / sales
3.0
FCF yield
11.9%
Dividend yield
—
Gross margin
82.0%
Operating margin
38.8%
Net margin
44.1%
Revenue growth (YoY)
+14.7%
Revenue growth (3-yr annual)
+7.5%
EPS growth (YoY)
—
FCF/share growth (YoY)
-11.5%
Beta
0.4
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
INVA earnings
Next report: Feb 24, 2027 (Q4 2026, EPS estimate $0.45).
Beat the EPS estimate in 3 of 4 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q3 2026
Nov 4, 2026
-$1.03
$0.34
-402.9%
$106.12M
Q2 2026
Aug 5, 2026
$0.56
$0.50
+12.0%
$119.59M
Q1 2026
May 6, 2026
$0.47
$0.43
+9.3%
$97.99M
Q4 2025
Feb 25, 2026
$0.47
$0.43
+9.3%
$114.61M
INVA analyst price target
Median target $34.00 from 6 analysts, ranging $18.00 – $46.00.
Nama's AI scorecard currently rates Innoviva Buy (8.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is INVA's P/E ratio?
Innoviva trades at a trailing price-to-earnings ratio of 39.2.
When does INVA report earnings?
Innoviva's next scheduled report is on Feb 24, 2027. Analysts expect EPS of $0.45.
What is the INVA price target?
The median analyst price target from 6 analysts is $34.00, with a range of $18.00 – $46.00.
Is INVA Shariah compliant?
Nama's AAOIFI-style screen reads Innoviva as Not Shariah Compliant. At least one of the three ratios or the industry test failed.